Related Experiment Video
Updated: May 4, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant
David M Livermore1, Marina Warner1, Shazad Mushtaq1
1Antimicrobial Resistance & Healthcare-Associated Infections Reference Unit, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Abstract:
Ceftaroline reportedly has lower minimum inhibitory concentrations (MICs) than established cephalosporins for Streptococcus pneumoniae. We further evaluated this activity using 155 pneumococci chosen by serotype and cefotaxime MIC. MICs were determined by agar dilution on Mueller-Hinton agar and Iso-Sensitest agar and by Etest. Inhibition zones were measured for 5 μg and 30 μg ceftaroline discs using both CLSI/EUCAST and BSAC methodology. Ceftaroline was more active than cefotaxime, with MICs 2-8-fold lower for isolates with cefotaxime MICs of ≤1 mg/L and mostly in the range 0.125-0.5 mg/L for those with cefotaxime MICs of 2 mg/L to ≥16 mg/L. Twelve isolates belonging to serotypes 14 (n=2), 19A (n=6) and 19F (n=4) were ceftaroline-resistant, with MICs of 0.5-1 mg/L. Essential agreement between MIC methods was excellent, with values on Iso-Sensitest agar and Mueller-Hinton agar identical ±1 doubling dilution in all cases, and with 154/155 values identical ±1 doubling dilution between agar dilution and Etest. Nevertheless, 5/11 isolates with agar dilution MICs of 0.5 mg/L (i.e. just resistant) 'had' MICs of 0.25 mg/L (just susceptible) by Etest. Inhibition zones also correlated with MICs, but discrimination around the breakpoint MICs was poor irrespective of method and disc type. In summary, the results confirm the good activity of ceftaroline against pneumococci, but susceptibility testing will present challenges in routine laboratories, with discs poorly discriminatory and with Etest prone to give susceptible results for isolates with MICs one doubling dilution above the breakpoint.
Insights
Ceftaroline shows good activity against Streptococcus pneumoniae, but susceptibility testing poses challenges. Routine labs may face difficulties with disc diffusion and Etest methods for accurate results.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Ceftaroline exhibits lower minimum inhibitory concentrations (MICs) against Streptococcus pneumoniae compared to existing cephalosporins.
- Streptococcus pneumoniae serotypes and cefotaxime MICs were used to select 155 isolates for evaluation.
Purpose of the Study:
- To further evaluate the in vitro activity of ceftaroline against Streptococcus pneumoniae.
- To assess the performance of different susceptibility testing methods for ceftaroline against pneumococci.
Main Methods:
- Minimum inhibitory concentrations (MICs) were determined using agar dilution on Mueller-Hinton and Iso-Sensitest agar, and Etest.
- Inhibition zones were measured using 5 μg and 30 μg ceftaroline discs with CLSI/EUCAST and BSAC methodologies.
Main Results:
- Ceftaroline demonstrated 2-8 fold lower MICs than cefotaxime for susceptible isolates and MICs mostly in the 0.125-0.5 mg/L range for resistant isolates.
- Twelve isolates (serotypes 14, 19A, 19F) were ceftaroline-resistant (MICs 0.5-1 mg/L).
- Essential agreement between MIC methods was excellent, but Etest yielded susceptible results for some borderline resistant isolates, and disc diffusion showed poor discrimination.
Conclusions:
- Ceftaroline exhibits potent activity against Streptococcus pneumoniae.
- Susceptibility testing of ceftaroline against pneumococci presents challenges for routine laboratories due to poor discrimination with disc diffusion and potential for false susceptible results with Etest.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024